Shots:

• The approval is based on P-III PARAGON-HF study involves assessing of Entresto (sacubitril/valsartan) in the treatment of patients with preserved ejection fraction HFpEF
• The expanded indication enables potential treatment of adults with left ventricular ejection fraction (LVEF) below normal- benefits are most clearly evident
• Entresto is the 1st and only therapy approved in the US to treat patients diagnosed with guideline defined heart failure to include both those with HFrEF and many with HFpEF

 ­ Ref: Novartis | Image: Novartis